49 articles with Gelesis
7/21/2021More money means more progress for potentially life-saving therapies. Here's a peek at some biopharma companies adding to their books this week.
The Boston-based company merged with Capstar Special Purpose Acquisition Corp. and will begin trading on the New York Stock Exchange under the ticker symbol “GLS.”
NAFLD Fibrosis Score (NFS) was developed to predict the presence of significant fibrosis using common clinical and laboratory values
Ms. Wildman brings extensive experience in brand building and marketing in the consumer health & wellness space, both at established market leaders and digitally native startups
Americans are nearly as worried about gaining weight between now and the end of the year (53%) as they are about not being able to see family for the holidays (54%)
Gelesis Presents Pre-Clinical Data Suggesting Proprietary Hydrogel (GS300 Prototype) Reverses the Damage to the Intestines Induced by a High Fat Diet
Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic metabolic diseases, released today a poster presentation on the therapeutic findings of its Gel-B (GS300) at The Liver Meeting, the American Association for the Study of Liver Disease’s (AASLD) annual conference.
New data show that pre-diabetes and impaired beta cell function were associated with a dysfunctional gut barrier, a potential precursor to metabolic diseases Additional analysis of the company’s pivotal GLOW study suggests fasting plasma glucose levels and insulin resistance could be strong predictors of weight loss with Plenity®
Plenity® Efficacy and Safety Data to be Presented at the European and International Congress on Obesity 2020
Plenity (Gelesis100) is an orally administered, non-stimulant, non-systemic aid in weight management based on proprietary hydrogel technology with a highly favorable safety and efficacy profile demonstrated in clinical studies Plenity is currently available in the U.S. in limited release with a full launch in 2021 BOSTON--( BUSINESS WIRE )-- Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat overweigh
Partnership includes $35 million up front licensing fees and equity investment, with future milestone payments of up to $388 million plus royalties
Gelesis , a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2020.
Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, and Ro, a leading U.S. telehealth provider, announced today they will partner to offer high-quality remote care dedicated to weight management and prescription fulfillment of Plenity
Vitruvian Partners leads a $63.4 million equity round, complemented by $21.2 million in new, non-dilutive grant funding and loans to further support commercialization efforts
Pivotal Data Presented at ObesityWeek 2019 Highlight the Therapeutic Benefits of PlenityTM in Adults with Obesity and Underscore its Safety and Efficacy in Lower-BMI Overweight Adults
Plenity-treated adults achieving a BMI of <27 lost an average of 13.5% of their weight with the rate of weight loss tapering as participants approached a healthy BMI goal
Gelesis announced that the Company will deliver two oral presentations and one poster at ObesityWeek 2019, the annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society in Las Vegas, Nevada, from November 3-7, 2019.
Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week
Gelesis announced the presentation of data from a clinical study demonstrating that GS500 prototype provided a significant reduction in colonic transit time in patients with chronic idiopathic constipation relative to placebo.
PureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week
PureTech Health plc announced that its affiliates Gelesis and Vedanta Biosciences will deliver poster presentations of clinical data at Digestive Disease Week, the world’s largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
PLENITY manufacturing facility will be the first factory to commercially produce medical super-absorbent hydrogels synthesized from naturally derived building blocks
PLENITY is FDA cleared for the largest number of adults struggling with overweight and obesity (BMI 25-40 kg/m2) of any prescription weight-management aid and the first that can be used, along with diet and exercise, in millions of overweight adults who have never before had prescription options
Gelesis Presents Preclinical Data Showing Proprietary Hydrogel Prevents Harmful Effects of a High-Fat Diet
Mice fed high-fat diet and treated with Gel-B (GS300 prototype) hydrogel were protected against the development of fatty liver and associated metabolic disorders
Treatment with Gelesis hydrogel prevented unwanted substances from entering the circulation in mice with severe gut wall injury